| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
The primary molecular target of Miramistin is the bacterial cell membrane. By utilizing its cationic properties, Miramistin binds to the negatively charged surface of bacteria, disrupting membrane integrity, inhibiting bacterial metabolism and growth, and inducing cell death. It also inhibits human 5α-reductase type 1 (5α-R1) with an IC50 of 4.28 μM, showing mixed inhibition through NADPH site binding confirmed by SPR.
|
|---|---|
| ln Vitro |
In vitro, Miramistin demonstrates broad-spectrum antimicrobial activity against gram-positive and gram-negative bacteria, fungi, and viruses. It disrupts bacterial cell membranes and inhibits bacterial metabolism. Additionally, it inhibits human 5α-R1 with an IC50 of 4.28 μM, 7.2-fold stronger than the rat enzyme, and shows mixed inhibition confirmed by SPR binding analysis.
|
| ln Vivo |
In vivo, Miramistin is used as a topical antiseptic and disinfectant for wound care, surgical scrubs, and environmental disinfection. It is not used systemically due to toxicity concerns. Its 5α-R1 inhibition activity suggests potential applications in androgen-related conditions, though this requires further investigation.
|
| Enzyme Assay |
For antimicrobial susceptibility testing, bacterial or fungal cultures are grown in appropriate media, and Miramistin is added at various concentrations. Growth inhibition is assessed by broth microdilution. MIC values are determined as the lowest concentration inhibiting visible growth.
|
| Cell Assay |
For 5α-reductase inhibition assays, human or rat 5α-R1 microsomes are incubated with Miramistin and NADPH. The substrate testosterone is added, and the conversion to dihydrotestosterone is measured by HPLC or LC-MS/MS. SPR analysis is performed to confirm NADPH site binding, and inhibition kinetics are analyzed by Lineweaver-Burk plots.
|
| Animal Protocol |
For in vivo studies, animal models of skin infection or wound infection receive topical Miramistin. Bacterial burden is quantified by colony counting. For 5α-R1 inhibition studies, rats receive Miramistin by systemic administration, and dihydrotestosterone levels in target tissues are measured by LC-MS/MS.
|
| References |
| Molecular Formula |
C26H47CLN2O
|
|---|---|
| Molecular Weight |
439.125
|
| Exact Mass |
438.338
|
| CAS # |
15809-19-5
|
| PubChem CID |
72949
|
| Appearance |
Light yellow to yellow solid
|
| LogP |
3.865
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
18
|
| Heavy Atom Count |
30
|
| Complexity |
388
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[Cl-].O=C(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H])N([H])C([H])([H])C([H])([H])C([H])([H])[N+](C([H])([H])[H])(C([H])([H])[H])C([H])([H])C1C([H])=C([H])C([H])=C([H])C=1[H]
|
| InChi Key |
JQQZCIIDNVIQKO-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C26H46N2O.ClH/c1-4-5-6-7-8-9-10-11-12-13-17-21-26(29)27-22-18-23-28(2,3)24-25-19-15-14-16-20-25;/h14-16,19-20H,4-13,17-18,21-24H2,1-3H3;1H
|
| Chemical Name |
benzyl-dimethyl-[3-(tetradecanoylamino)propyl]azanium;chloride
|
| Synonyms |
Miramystin Miramistin
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~100 mg/mL (~227.7 mM; with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2772 mL | 11.3861 mL | 22.7723 mL | |
| 5 mM | 0.4554 mL | 2.2772 mL | 4.5545 mL | |
| 10 mM | 0.2277 mL | 1.1386 mL | 2.2772 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
